BFM
CMPX icon

Boothbay Fund Management’s Compass Therapeutics CMPX Stock Holding History

Boothbay Fund Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-212,300
Closed -$403K – 1498
2025
Q1 		$403K Buy
+212,300
New +$565K 0.01% 945

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Boothbay Fund Management's CMPX Position: Q1 2026 in Review

Boothbay Fund Management sold out of Compass Therapeutics (CMPX) in Q1 2026, closing a stake of 205,024 shares — an estimated $1.1M sold.

Boothbay Fund Management first reported a position in CMPX in Q4 2022 and held it in 3 quarters. The position peaked at $1.1M in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Boothbay Fund Management reported no remaining Compass Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 205,024 Compass Therapeutics shares in Q1 2026, an estimated $1.1M.
  • Boothbay Fund Management first reported a position in Compass Therapeutics in Q4 2022 and held it in 3 quarters.
  • Boothbay Fund Management's Compass Therapeutics position peaked at $1.1M in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.